legal concern weigh johnson johnson media
page full analyst note dec
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research dec
estim oct
price data dec
rate updat dec
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
johnson johnson stand alon leader across major
base develop research pipelin except cash flow
gener togeth creat wide econom moat
 hold leadership role divers healthcar segment
includ medic devic over-the-count product sever
pharmaceut market contribut total
revenu pharmaceut divis boast sever industry-lead
drug includ immunolog drug remicad psoriasi drug
stelara medic devic group bring one third
sale compani hold control posit mani
area includ orthoped ethicon endo-surgeri surgic
devic consum divis larg round remain
busi line despit manufactur issu past
sever year group still hold mani brand strong price
research develop effort result next-gener
product pharmaceut group recent launch sever
new blockbust howev rel compani size
need increas number meaning drug late-stag
develop support long-term growth compani also
minim invas surgic tool
expenditur sale strong cash gener
enabl firm increas dividend past half
centuri expect continu also allow take
advantag acquisit opportun augment growth
divers oper segment coupl expect new product
insul compani patent loss rel
pharma firm contrast peer face
major near-term patent loss hard-to-mak
complex drug like slow gener competit
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
johnson johnson world largest divers healthcar
compani three divis make firm pharmaceut medic devic
diagnost consum drug devic group repres close
sale drive major cash flow firm drug
divis focus follow therapeut area immunolog oncolog
neurolog pulmonari cardiolog metabol diseas devic
segment focus orthoped surgeri tool vision care
smaller area last segment consum focus babi care beauti
oral care over-the-count drug women health geograph
close half total revenu gener within unit state
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
legal concern weigh johnson johnson media
media report highlight legal concern johnson
johnson talc powder weigh stock price
expect major chang fair valu estim
base report johnson johnson face
case relat use talc powder caus person
injuri cancer mani case legal issu
front compani mani year expect
case litig sever year case
alreadi decid shown mix outcom close
half verdict go compani
half support compani expect case
appeal litig compani alreadi
establish legal defens accrual help litig
case overal expect legal case
disrupt wide moat firm sourc moat
innov brand power howev brand power
consum relat product may feel
increas pressur case continu
media report sever relationship johnson
 johnson talc powder asbesto cite could
lead health problem believ rigor
test year provid legal protect
major case uncertainti remain
around credibl legal claim made
believ major case motiv
tri link unrel diseas talc powder use
effort gain settlement litig
case one one expect wear
plaintiff group end settlement caus
major impact compani stock price remind
 face litig concern surround
metal-on-met hip compani success navig
payment billion dollar without caus major
impact valuat
increas fair valu estim per share
base improv outlook overal margin
partli driven strong margin compani drug
divis within core driver cash flow new
immunolog oncolog drug drive growth
includ actelion acquisit expect annual
earn per share growth averag next
five year strong growth new pipelin drug
off-set patent loss pharmaceut divis
near term result actelion acquisit
bring high-margin drug also expect wane
cost-remedi effort consum group
increas cost-contain effort throughout firm
help off-set margin pressur due loss patent
protect sever high-margin drug
larg basi low volatil cash flow
divers inelast product portfolio rate johnson
 johnson uncertainti low scenario analysi
assum base-cas fair valu estim bull
case probabl bear case
probabl project fair valu estim rel
base case scenario analysi show minor varianc
henc low fair valu uncertainti rate key factor
affect scenario analysi includ degre
success drug pipelin along magnitud
market pressur current market drug
importantli potenti pressur remicad
biosimilar unknown regulatori impact on-going
litig surround devic also weigh certainti
believ johnson johnson carri one widest
moat healthcar sector support intellectu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
johnson johnson effort support robust revenu
base pharmaceut compani recent launch
sever new blockbust allow johnson
johnson escap larg unscath upcom patent
expir effort medic devic includ
minim invas surgic tool help maintain
leadership sever medic devic area well
remain high sever devic product
exampl physician switch vendor hip knee
devic could take week month learn new
product keep physician tie compani
consum side new product
advanc combin solid brand power
reinforc market campaign sustain solid
compani face manag patent loss next
year price power core franchis
rel stabl turn macro environ
compani face sever headwind make solid
strateg move address challeng neg
side risk-sensit food drug administr
gener approv safe drug drug
high-ne area cancer also managed-car
pharmaci benefit manag consolid past
decad use grow size demand
lower drug price reduc coverag less innov
drug forc drug firm push true innov
reduc power compani distribut network
 govern evalu compar
effect program aggress price
negoti rais bar futur innov
johnson johnson face sever headwind pipelin
focus innov treatment area unmet
medic area oncolog immunolog
payer coverag price power remain strong outsid
properti drug group switch cost devic
segment strong brand power consum group
compani divers revenu base strong pipelin
robust cash flow gener creat wide econom
candid smaller biotechnolog compani look
partner new drug strengthen johnson
johnson abil bring new product market
johnson johnson divers oper major pillar
support wide moat compani hold leadership
role number segment includ medic devic
over-the-counter medicin sever drug market
compani overli depend one particular oper
segment pharmaceut busi medic devic
group consum product repres
total sale respect addit within
segment one product domin sale lipitor
despit carri lower-margin divis
maintain strong price power post gross
margin past five year valid
strong competit posit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
pipelin strong entrench medic devic
consum good give firm relief
pressur drug group
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
oth major near-term patent loss
product hard manufactur includ
biolog drug remicad limit gener
oproduct litig manufactur issu
power brand name segment brand
recognit import
odivers healthcar segment help insul
downturn economi offer defens
growth opportun steadi like grow
osever johnson johnson key drug
pipelin drug specialti drug tend carri
strong price power well lower regulatori
hurdl approv
oleg action regard product recal hip knee
replac along sever consum product
could damag compani brand power cost
billion dollar creat distract
osever johnson johnson import drug
face increas competit could slow
growth rate drug group
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
johnson johnson hold one strongest financi
posit healthcar sector recent acquisit
actelion put dent compani cash balanc
annual free cash flow approach billion
compani sound financi shape even expect
bolt-on acquisit share repurchas
compani remain solid financi foot
oper standpoint patent loss mitig sever
divers oper line medic devic consum
product cash flow remain rel stabl
addit expect share repurchas next
sever year draw share count
johnson johnson need overcom sever roadblock
product metal-on-met hip knee implant
sever product recal could damag sterl
reput longer term compani face typic
healthcar risk reduc price power
govern pharmaci benefit manag regulatori
delay nonapprov well increasingli aggress
gener competit small-molecul drug
biolog particular biosimilar risk remicad
increas sever biosimilar work gain market
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
ceo/director/chairman
chairman board divisional/
repres date owner name posit common share held report holder issuer
america corpor
share
fund
share
fund
overal view stewardship johnson johnson
rel standard firm good record
make sound capit deploy decis
consist gener return invest capit
cost capit major recal recent potenti
overpay actelion poor turnaround time
address manufactur problem certain key divis
lead us balanc view compani
weldon step top posit
lead johnson johnson sinc given
weldon age rigor process find successor
see chang leadership red flag gorski
bring strong record industri experi date back
began industri pharmaceut
johnson johnson
subsequ advanc mani manag
posit drug devic divis johnson
johnson along manageri post novarti give
broad experi need run massiv health
conglomer first major test gorski leadership
billion acquisit orthoped devic firm
synth larg driven gorski head
johnson johnson devic unit believ
acquisit ad import exposur emerg market
trauma devic appear small
impact valuat price paid synth larg
account
increment benefit gain
acquisit second major test gorski recent
complet actelion deal skeptic
abl creat much valu sharehold due high
take-over price rel fair valu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
johnson johnson post steadi patent loss
like weigh futur growth oct
slightli ahead consensu expect result
project expect major
chang fair valu estim oper sale growth
led drug group
addit gain consum devic
steadi gain across group help reinforc
wide moat howev view compani slightli
overvalu expect top-lin growth moder
next two year patent pressur weigh
drug group combin rel modest late-stag
drug group broad strength across drug
support division growth immunolog drug
remicad total sale continu lose price power
due biosimilar pressur remicad held
volum continu sale
declin suggest close annual price declin
offset weak remicad oncolog divis
continu post strong gain led imbruvica darzalex
zytiga howev expect gener pressur zytiga
sale later year despit patent loss
pressur expect drug group post close
annual growth
outsid drug group consum growth solid
medic devic group continu lag expect
strength consum tie stock
well aggress discount base neg
margin trend group howev need see
consist increas long-term growth rate
divis devic side price pressur
lack innov creat headwind group
longer term introduct robot data
within devic divis hold potenti reacceler
growth beyond limit data product
temper long-term growth rate
complet overview compani posit
immunolog oncolog therapeut area well
deep dive compani pipelin pleas see
threat secur pharma moat
pharma moat outlook compani still strong
analysi pharma compani continu
see industri well posit strong econom
moat analysi reaffirm moat
rate increas bayer moat wide
narrow bayer divestitur materi scienc group
combin strong drug busi well-posit
bolster monsanto
acquisit led us upgrad moat rate wide
moat pharma compani
increas focu innov area unmet medic
need enabl strong price power off-set increas
negoti power pharmaci benefit manag
 restrict price develop market outsid
 drug carri patent protect allow firm
charg near monopolist price drug true price
power determin sever factor includ benefit
patient uniqu govern outsid
 pbm within increasingli push
back drug price medicin lack signific
benefit overal stronger drug uniqu
efficaci stronger drug price power result
major drug compani focus
develop effort area signific unmet medic
addit segment within pharma firm anim
health consum healthcar carri strong moat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
cancer drug sale outsid drug modest growth
consum devic larg expect
competit pressur weigh growth
expect trend continu
eps increas strong sale
gain higher margin drug group help amplifi growth
bottom line expect trend continu
johnson johnson drug unit best posit growth
next three year addit face
potenti heavi legal charg firm talcum
powder potenti caus cancer expect johnson
johnson litig case aggress final
relat payment caus major impact
complet overview compani posit
immunolog oncolog therapeut area well
deep dive compani pipelin pleas see
threat secur pharma moat
augment moat strength deriv human brand
drug segment overal moat analysi guid
under-valued call bayer glaxosmithklin
valuat
complet overview pharma moat analysi
pleas see report pharma moat outlook compani
still strong posit analyz key point
around moat larg pharmaceut industri
buoy strong drug group sale
line expect consensu
expect major chang fair valu
estim continu view stock larg fairli
valu invest commun appreci
compani strength weak quarter steadi
result reaffirm wide moat rate
led strong drug sale total sale increas
oper year year drug group
growth slightli higher expect driven
robust immunolog oncolog drug sale howev
expect growth therapeut area moder
expect price declin immunolog drug
remicad due biosimilar pressur estim
caus remicad price declin close alreadi
also expect growth immunolog drug stelara
stagnat share gain crohn indic led
strong clinic data off-set share loss psoriasi
due increas competit drug oncolog
increas gener competit zytiga expect
fourth quarter ahead manag guidanc velcad
expect pressur compani overal
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
equival
net properti plant equip
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
